The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Long-term outcomes of valve-in-valve transcatheter aortic valve implantation for degenerate homograft aortic valve replacement

EuroIntervention 2020;16:e760-e762. DOI: 10.4244/EIJ-D-20-00450

1. Heart Division, The Royal Brompton Hospital, London, United Kingdom


Introduction

“Valve-in-valve” transcatheter aortic valve implantation (ViV-TAVI) is an alternative to conventional redo surgery for bioprosthetic aortic valve replacement (AVR) dysfunction1 but ViV-TAVI for degenerate stentless bioprostheses is challenging2. We report the five-year follow-up of a single-centre consecutive series of patients undergoing ViV-TAVI for degenerate homograft AVR.

Methods

All patients receiving ViV-TAVI for degenerate homograft AVR between October 2009 and April 2019 were retrospectively analysed. Clinical, echo, and brain natriuretic peptide (BNP) levels were measured preprocedurally and after 1, 3, and 5 years. The Royal Brompton and Harefield Clinical Practice Committee approved the study protocol, the study was performed ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
The retro-antegrade approach to paravalvular leak closure after transcatheter aortic valve replacement